Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial).

@article{Yamada2013FeasibilitySO,
  title={Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial).},
  author={Kyosuke Yamada and Hiroshi Tanabe and Manami Imai and Toshiko Jobo and Kazuya Kudo and Hiroyuki Fujiwara and Chie Nagata and Kenichi Furuya and Mitsuaki Suzuki and Kazunori Ochiai and Tadao Tanaka and Makoto Yasuda},
  journal={The journal of obstetrics and gynaecology research},
  year={2013},
  volume={39 1},
  pages={311-6}
}
AIM The optimal chemotherapy regimen for patients with endometrial cancer has not been established. We assessed the feasibility of paclitaxel plus carboplatin (TC) for postoperative chemotherapy in patients with endometrial cancer. MATERIAL AND METHODS Patients with newly diagnosed endometrial cancer received TC (paclitaxel 180 mg/m(2) , carboplatin AUC6 mg/mL/min) every three weeks. Treatment was continued until disease progression or completion of six cycles. Toxicities were evaluated every… CONTINUE READING